



PUTTING HEALTH ECONOMICS
THEORY INTO PRACTICE
CONNECT:
HEALTH ECONOMICS
WORKSHOP 2014

HEALTH ECONOMICS FROM
THEORY TO PRACTICE:

Informing Related Decisions of
Reimbursement, Research and
Regulation

A THREE-DAY WORKSHOP

Conducted by
Professor Simon Eckermann and
Professor Andrew Willan

2–4 April 2014

Sydney Business School, Sydney, Australia

Suitable for

Evaluators of health technology assessment, health economists, pharmacoeconomists, applied economists, clinicians and researchers designing RCTs, decision and policy makers.

What is the workshop?

The course teaches best practice for addressing reimbursement (Day 1), research (Day 2) and regulation (Day 3) decisions in processes associated with health technology assessment.

Objectives

Using seminars and tutorial-based learning with methods provided in Excel spreadsheets, the course provides participants with knowledge, practical skills and materials to:

1. Undertake analysis of clinical trials to optimally inform evidence-based decision making under uncertainty in processes of health technology assessment (HTA), such as that for NICE, PBAC etc., for direct and indirect comparisons.
2. Design clinical trials to optimally inform decision making within and across jurisdictions using value of information methods conditional on decision context, including time, opportunity costs and option value of delay and imperfect implementation.
3. Compare multiple strategies, including construction and use of expected net-loss curves and frontiers, to optimally inform risk-neutral and risk-averse decision making.
4. Undertake efficiency measurement across health-care providers, such as hospitals, consistent with maximising net benefit.

- Eckermann, S., Coelli, T. 2013. 'Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice'. *Social Science & Medicine*. 76: 159–168.
- Eckermann, S., Willan, A. 2013. 'Optimal global VOI trials: better aligning manufacturer and decision maker interest and enabling feasible risk sharing'. *PharmacoEconomics*. 31: 393–401.
- Eckermann, S., Willan, A. 2011. 'Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies'. *PharmacoEconomics*. 29(7): 563–577.
- Eckermann, S., Coory M, Willan A. 2011. 'Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest'. *PharmacoEconomics*. 21(10): 1183–1195. doi:10.1002/hec.1781.
- Willan, A.R., Eckermann S. 2011. 'Accounting for between-study variation in incremental net benefit in value of information methodology'. *Health Economics*. 21(10): 1183–1195. doi: 10.1022/hec.1781.
- Willan, A., Eckermann, S. 2012. 'Expected value of information and pricing new health care interventions'. *PharmacoEconomics*. 30(6): 447–459.
- Eckermann, S., Karnon, J., Willan, A. 2010. 'The value of Value of Information: best informing research design and prioritization using current methods'. *PharmacoEconomics*. 28(9): 699–709.
- Willan, A.R., Eckermann, S. 2010. 'Optimal clinical trial design using value of information with imperfect implementation'. *Health Economics*. 19: 549–561.
- Eckermann, S., Willan, A.R. 2009. 'Globally optimal trial design for local decision making'. *Health Economics*. 18: 203–216.
- Eckermann S, Coory M, Willan AR. 2009. 'Indirect comparison: relative risk fallacies and odds solution'. *Journal of Clinical Epidemiology*. 62: 1031–1036.
- Eckermann, S., Briggs, A., Willan, A.R. 2008. 'Health Technology Assessment in the Cost-Disutility Plane'. *Medical Decision Making*. 28: 172–181.
- Eckermann, S., Willan, A.R. 2008, 'Time and Expected Value of Sample Information Wait for No Patient'. *Value in Health*. 11: 522–526.
- Eckermann, S., Willan, A.R. 2008, 'The Option Value of Delay in Health Technology Assessment'. *Medical Decision Making*. 28: 300–305.
- Willan, A.R., Kowgier, M.E. 2008. 'Determining optimal sample sizes for multi-stage randomized Clinical Trials using value of information methods'. *Clinical Trials*, 5: 289–300.
- Willan, A.R. 2008. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials*. 5: 587–594.
- Eckermann, S., Willan, A.R. 2007, 'Expected Value of Information and Decision Making in HTA'. *Health Economics*. 16: 195–209.
- Willan, A.R. 2007, 'Clinical decision making and the expected value of information'. *Clinical Trials*. 4: 279–285.
- Willan, A.R., Briggs, A. 2006. *Statistical analysis of cost effectiveness data*. Wiley.

DAY 1: EVIDENCE-BASED REIMBURSEMENT: DECISION MAKING UNDER UNCERTAINTY

8.45–9.00	Arrival with tea and coffee
9.00–9.15	Course Introductions
9.15–10.15	Principles and practice of economic evaluation in health technology assessment: Thinking outside the box
10.15–10.30	<i>Morning Coffee</i>
10.30–11.45	Statistical analysis of cost-effectiveness data from clinical trials
11.45–12.15	Tutorial: Modelling Uncertainty
12.15–1.00	<i>Lunch</i>
1.00–2.00	Frankenstein's Monster or Vampire of trials: coverage, comparability and avoiding inferential fallacies
2.00–2.45	Decision Analysis and Decision Tree Methods
2.45–3.15	Tutorial: Probabilistic Sensitivity Analysis (PSA) – from parameter uncertainty to decision uncertainty
3.35–3.30	<i>Afternoon Coffee</i>
3.30–5.00	Why a Bayesian be?

DAY 2: RESEARCH AND REIMBURSEMENT: OPTIMAL TRIAL DESIGN WITHIN AND ACROSS JURISDICTIONS

9.00–10.30	The value of information (Vol) to decision makers and principles for efficient trial design
10.30–10.45	<i>Morning Coffee</i>
10.45–11.30	Tutorial: Vol
11.30–12.15	Value of information and best informing societal decisions when comparing more than two strategies: The cost-disutility plane and expected net loss curves and frontiers.
12.15–1.00	<i>Lunch</i>
1.00–1.30	Tutorial: ENL Curves and frontiers
1.30–2.15	Joint research and reimbursement decisions
2.15–3.00	Optimal global trial design and decision making
3.00–3.15	<i>Afternoon Coffee</i>
3.15–4.15	Vol and the pricing of interventions
4.15–5.00	Vol and pricing with optimal global trial design: Betteraligning manufacturer and decision maker interest and enabling robust risk sharing

DAY 3: RESEARCH, REIMBURSEMENT AND REGULATION: TRANSLATING

9.00–10.15	The net benefit correspondence theorem: creating incentives for evidence based medicine in practice
10.30–11.00	<i>Morning Coffee</i>
11.00–12.30	Tutorial: Comparing provider efficiency in practice consistent with maximising benefit
12.30–1.30	<i>Lunch</i>
1.30–2.30	Bridging the Silos: Funding quality for net benefit within a budget
2.30–3.00	An economically meaningful threshold value
3.00–3.30	Panel summary and question session

Professor Andrew Willan

SickKids Research Institute/University of Toronto

Dr Willan is an academic biostatistician and clinical trial methodologist. He is Senior Scientist at SickKids Research Institute, Professor of Biostatistics in the Dalla Lana School of Public Health at the University of Toronto and Professor Emeritus in the Department of Clinical Epidemiology and Biostatistics at McMaster University.

His contributions to statistical methodology include publications in the areas of cost-effectiveness analysis, value of information methods, management trials, crossover trials, non-nested regression analysis and bivariate response models. He has been particularly instrumental in devising robust methods for modelling uncertainty in economic evaluation and interpreting such evidence for decision making in health technology assessment through the use of value of information methods.

Previously held positions include the Head of Biometry of the Clinical Trials Program at the National Cancer Institute of Canada and the Head of Clinical Trials and Epidemiology for the Cancer Program at Sunnybrook Medical Centre in Toronto. www.andywillan.com



Professor Simon Eckermann

Sydney Business School

Simon Eckermann is Professor of Health Economics at the University of Wollongong and adjunct Professor at Flinders University, and was previously Senior Health Economist at the NHMRC Clinical Trial Centre, Sydney University. He has extensive experience in undertaking original and applied research with health economic methods in Health Technology Assessment (HTA) and practice. His original research includes:

- (i) value of information methods for optimally informing joint reimbursement and research decisions by society decision makers and industry locally and globally with Professor Willan (<http://www.andywillan.com>)
- (ii) methods for consistently estimating absolute risk differences to overcome inferential fallacies identified with use of relative risk in indirect comparisons and translating evidence;
- (iii) the expected net loss frontier and comparison on the cost-disutility plane to best inform risk neutral or risk averse decision makers when comparing more than two strategies in HTA;
- (iv) a correspondence method allowing efficiency measures of health care providers or health systems in practice consistent with the maximisation of net benefit underlying evidence-based care.

More generally, this research has demonstrated links between optimal decision making in research, reimbursement and regulation. Associated methods have been taught by Professor Eckermann as part of the internationally acclaimed 3-day short course "Health Economic Method from Theory to Practice: informing related decisions of research, reimbursement and regulation" with Professor Willan since 2005.



Simon also actively sits on and undertakes guideline revision and health economics educational activities for National decision bodies such as the PBAC Economic Sub-Committee (2005–2010), Palliative Care Trials Scientific Committee (2006–current), Protheses List Advisory Committee (2010–2012) and is a CI on competitive research grants totalling more than A\$20 million.

REGISTRATION FORM

This document is an Australia Tax Invoice for GST purpose on completion and payment:
University of Wollongong BSB 082-886 • Account Number 038110002

Name
Organisation
Postal Address
Telephone Mobile
E-mail

I wish to register for the Three-Day Health Economics from Theory to Practice : Informing Related Decision of Reimbursement, Research and Regulation Workshop (please cross X)

Three-Day Workshop Fees Include all seminar and tutorial teaching materials, plus lunch each day.

Early Bird Fee till 20 December 2013

Fee from 20 December 2013

- | | |
|--|--|
| <input type="checkbox"/> Academic / Public Sector: AUS\$995.00 | <input type="checkbox"/> Academic / Public Sector: AUS\$1140.00 |
| <input type="checkbox"/> Private / Commercial Sector: AUS\$1990.00 | <input type="checkbox"/> Private / Commercial Sector: AUS\$2140.00 |
| <input type="checkbox"/> I wish to purchase a copy of the recommended text (AUS\$115.00)
<i>Statistical Analysis of Cost Effectiveness Data</i> by Willan and Briggs (2006) | |

I wish to pay by:

Cheque / money order (payable to University of Wollongong)

Credit Card (Visa / Master Card / Bankcard)

Type of card: Name on card:

Card number:/// Expiry date:

Signature of card holder: Credit card amount: AUD\$

Any special dietary requirements? (Please circle)

Vegetarian / Gluten Free / Lactose Free / Halal / Other (Please provide details)

.....

Please complete this application form and return it with payment of course fees to:

Kathryn Owen

Sydney Business School
Faculty of Business
University of Wollongong NSW 2522
t: +61 2 4221 3666
e: sbs-admin@uow.edu.au

Registration Closing Date

4 March 2014 — Early Bird 20 December 2013

Cancellation Policy

A refund will be returned less AUD\$100 administration fee for a cancellation up to 4 March 2014.
THERE WILL BE NO REFUNDS given after 4 March 2014.

Workshop size strictly limited to 25 delegates.